"Immunotherapy" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Manipulation of the host's immune system in treatment of disease. It includes both active and passive immunization as well as immunosuppressive therapy to prevent graft rejection.
| Descriptor ID |
D007167
|
| MeSH Number(s) |
E02.095.465.425
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Immunotherapy".
Below are MeSH descriptors whose meaning is more specific than "Immunotherapy".
This graph shows the total number of publications written about "Immunotherapy" by people in this website by year, and whether "Immunotherapy" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 1 | 1 |
| 1995 | 1 | 1 | 2 |
| 1996 | 1 | 0 | 1 |
| 1998 | 0 | 3 | 3 |
| 1999 | 2 | 1 | 3 |
| 2000 | 3 | 2 | 5 |
| 2001 | 2 | 5 | 7 |
| 2002 | 2 | 3 | 5 |
| 2003 | 2 | 4 | 6 |
| 2004 | 5 | 8 | 13 |
| 2005 | 3 | 2 | 5 |
| 2006 | 4 | 2 | 6 |
| 2007 | 4 | 1 | 5 |
| 2008 | 7 | 6 | 13 |
| 2009 | 4 | 2 | 6 |
| 2010 | 7 | 5 | 12 |
| 2011 | 5 | 5 | 10 |
| 2012 | 8 | 7 | 15 |
| 2013 | 8 | 9 | 17 |
| 2014 | 9 | 9 | 18 |
| 2015 | 9 | 16 | 25 |
| 2016 | 20 | 2 | 22 |
| 2017 | 22 | 3 | 25 |
| 2018 | 31 | 14 | 45 |
| 2019 | 28 | 16 | 44 |
| 2020 | 19 | 25 | 44 |
| 2021 | 22 | 20 | 42 |
| 2022 | 2 | 30 | 32 |
| 2023 | 3 | 31 | 34 |
| 2024 | 14 | 20 | 34 |
To return to the timeline,
click here.
Below are the most recent publications written about "Immunotherapy" by people in Profiles.
-
Systematic review of immune checkpoint inhibitor-related gastrointestinal, hepatobiliary, and pancreatic adverse events. J Immunother Cancer. 2024 Nov 14; 12(11).
-
Age-Associated Contraction of Tumor-Specific T Cells Impairs Antitumor Immunity. Cancer Immunol Res. 2024 Nov 04; 12(11):1525-1541.
-
NCCN Guidelines® Insights: Management of Immunotherapy-Related Toxicities, Version 2.2024. J Natl Compr Canc Netw. 2024 Nov; 22(9):582-592.
-
Dendritic cell-intrinsic PTPN22 negatively regulates antitumor immunity and impacts anti-PD-L1 efficacy. J Immunother Cancer. 2024 Oct 26; 12(10).
-
Non-small-cell lung cancer. Nat Rev Dis Primers. 2024 Sep 26; 10(1):71.
-
Immunotherapy vs Best Supportive Care for Patients With Hepatocellular Cancer With Child-Pugh B Dysfunction. JAMA Oncol. 2024 Sep 01; 10(9):1253-1258.
-
NKG2C/KLRC2 tumor cell expression enhances immunotherapeutic efficacy against glioblastoma. J Immunother Cancer. 2024 Aug 30; 12(8).
-
Clinical and molecular correlates of tumor aneuploidy in metastatic non-small cell lung cancer. Sci Rep. 2024 08 21; 14(1):19375.
-
Gynecological cancer tumor Microenvironment: Unveiling cellular complexity and therapeutic potential. Biochem Pharmacol. 2024 11; 229:116498.
-
Therapy-Induced Cellular Senescence: Potentiating Tumor Elimination or Driving Cancer Resistance and Recurrence? Cells. 2024 Jul 30; 13(15).